Introduction
Combined deficiency of factor V and factor VIII (F5F8D) was first described in a family by Oeri et al. in 1954 1 . Most patients have plasma levels of factor V (FV) and factor VIII (FVIII) (both antigen and activity) in the range of 5 to 30 U/dl, and exhibit mild to moderate bleeding manifestations 2 We recently identified a second gene (MCFD2) that accounted for most of the remaining families without mutations in LMAN1 6 . LMAN1 and MCFD2 form a stable, calciumdependent complex that likely serves as a cargo receptor for efficient ER-to-Golgi transport of FV and FVIII. Cargo receptors selectively package secreted proteins into COPII-coated vesicles budding from the ER for trafficking to the Golgi compartment [7] [8] [9] .
Consistent with this idea, FVIII was shown to bind to both LMAN1 and MCFD2 through calcium-dependent protein-protein interactions in cultured cells 10, 11 . The B domain of FVIII appears to be the primary determinant of binding to the LMAN1-MCFD2 complex 6, 12 . In vitro data suggest that the other cargo proteins including the lysosomal proteins cathepsin Z 13 and cathepsin C 14 , may also depend on LMAN1/MCFD2 function, though evidence for deficiency of these or other proteins in F5F8D patients has not been reported. LMAN1, but appears to still retain the ability to bind FVIII 11 .
We now report the analysis of 20 F5F8D families, including 10 families previously reported to lack LMAN1 mutations 4, 5 . Novel mutations in LMAN1 and MCFD2 were identified, including evidence for regulatory mutations that abolish LMAN1 mRNA expression. In addition, we studied the interaction of LMAN1 and MCFD2 in lymphoblasts derived from a patient with the I136T mutation in MCFD2 and a patient with a novel missense mutation in LMAN1 (C475R).
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MATERIALS AND METHODS
Patient samples. Peripheral blood (10-15 ml) was collected from the affected individuals after diagnosis of F5F8D with informed consent from all individuals. The study protocol was approved by the institutional review board at the University of Michigan. The levels of FV and FVIII activities are reported in Table 1 . Epstein-Barr virus (EBV) immortalized lymphoblast lines were derived from three affected individuals (family 9, ref 6 , B16, B17) as previously described 3 .
Sequencing of the LMAN1 and MCFD2 genes in F5F8D patients. All coding exons and intron-exon junctions were amplified from genomic DNA prepared from peripheral blood as previously reported. PCR reactions were performed as previously described 3, 6 and DNA sequencing completed in the University of Michigan DNA Sequencing Core. Total RNA was prepared from patient-derived lymphoblasts using the Trizol reagent (Invitrogen). RT-PCR reactions were performed as previously described 6 , using primers listed in Table 2 . Heterozygous mutations were confirmed by cloning PCR products and sequencing individual clones.
Immunoprecipitation and Western blot analysis.
Patient-derived lymphoblasts were lysed and immunoprecipitated with rabbit anti-MCFD2 6 or monoclonal anti-LMAN1 antibodies (a gift from H-P Hauri, University of Basel, Switzerland) as previously described 6 . The immunoprecipitates were further analyzed by Western blot with monoclonal anti-MCFD2 6 or rabbit anti-P58 (a gift from R.F. Pettersson, Karolinska Institute, Sweden).
For personal use only. 
Results

Further analysis of previously reported F5F8D patients
Previous LMAN1 gene sequence analysis failed to identify mutations in 17 of 54 F5F8D families 4, 5 . Ten of these families were studied in our recent report, which identified MCFD2 mutations in 7 families 6 . No LMAN1 or MCFD2 mutations were identified in the remaining three families, raising the possibility of additional locus heterogeneity and the involvement of a third F5F8D gene. One of the three families (family 2, ref 6 ), exhibited evidence for linkage to the MCFD2 locus 6 , suggesting a mutation in a regulatory region of the gene that was missed by direct sequence analysis. We sequenced the MCFD2 gene of the probands from the remaining 7 of the 17 previously reported F5F8D families 4,5 described above (renumbered as B2-B8, Table 1) and identified mutations in 4 families. A novel homozygous mutation (-6-1G→C) that abolishes the consensus splice acceptor site of MCFD2 exon 2 was identified in family
B6
. Homozygosity for a previously identified splice donor site mutation (149+5G→A) was identified in three Italian families (B3-B5). No LMAN1 or MCFD2 mutations were identified in families B2, B7 and B8. Genotyping revealed that the proband of family B2, whose parents are first cousins, is homozygous at the LMAN1 locus and heterozygous at the MCFD2 locus (Table 3) , suggesting an unidentified LMAN1 mutation. Although no mutation was identified in B7, Western blot analysis of the proband detected no LMAN1 protein (Fig. 1A) 4 . Immunoprecipitation of cell lysates from 5 X 10 6 lymphoblasts derived from the B7 proband also failed to detect LMAN1 (Fig. 1B) , suggesting a regulatory mutation in the LMAN1 gene that was missed by direct sequence analysis.
Indeed, RT-PCR detected only a trace amount of LMAN1 mRNA, and revealed an aberrantly-spliced species of LMAN1 mRNA that skipped exon 4 (Fig. 2) . The low level of mRNA in this patient may be the result of nonsense-mediated decay. Reevaluation of the B8 proband revealed reduced von Willebrand factor and FVIII levels and a normal level of FV, consistent with a diagnosis of the von Willebrand disease.
Mutational analysis of additional F5F8D patients
We analyzed the LMAN1 and MCFD2 genes of 11 F5F8D patients from 10 previously unreported families (B9-B18, Table 1 ). These families included the first reported cases from the Balkans, Austria, Poland, Belgium, Argentina and Greece.
Homozygosity for LMAN1 null mutations were identified in 5 families, including 3 novel mutations (780delT in B12 and 839-841delA in B14, and E321X in B13), and 2 previously reported mutations (T2→C in B11 and 822+1G→A in B15). We also identified homozygous MCFD2 mutations in 2 families from the former Yugoslavia (B9-B10) and a family from Greece (B18). B9 carries a missense mutation (I136T) that has For personal use only. on July 14, 2017. by guest www.bloodjournal.org From previously been reported in a Venezuelan family 6 . B10 carries the 149+5G→A splicing mutation identified above in 3 Italian families and previously in US, Swiss and Indian families 6, 16 . To examine the genetic origin of this mutation, we constructed haplotypes using 3 single nucleotide polymorphisms in the 3' UTR of MCFD2 and 3 microsatellite markers (BZ1, located ~570 kb upstream of MCFD2; D2S2227, located ~123 kb downstream of MCFD2 and BZ20, located ~1,900 kb downstream of MCFD2). Among 6 families with the 149+5G→A mutation, five different haplotypes were identified, indicating at least five independent origins for this mutation (Table 3) . These data are consistent with distinct geographic origins for many of these families and suggest a recurring mutation, perhaps due to a mutation hotspot at a CpG dinucleotide 17 . The haplotypes of the two families (B9 and 9II-5, ref 6 ) with the I136T missense mutation in MCFD2 diverge at both the BZ1 and D2S2227 markers ( Table 3 ), suggesting that this mutation also arose independently. Lastly, B18 carries a novel homozygous missense mutation (D86A) that changes an amino acid at a position in the first EF hand domain that is invariant in all MCFD2 orthologs 6 . Though cells from family B18 are not available for study, we expect the D86A mutation to abolish binding of the mutant MCFD2 to LMAN1, similar to previously described D129E and I136T mutations 6 .
Western blot analysis of lymphoblasts derived from the proband of family B16 detected no LMAN1 (Fig. 1A) , indicating that loss of LMAN1 protein expression is the cause of F5F8D in this patient. Sequencing of the genomic DNA detected no mutations within the exons or splice junctions of the LMAN1 and MCFD2 genes. We isolated mRNA from lymphoblasts and performed RT-PCR analysis, identifying an alternatively spliced species of LMAN1 mRNA (Fig. 2) . Sequencing confirmed that the lower band 
Family
Haplotype Mutation
For personal use only. on July 14, 2017. by guest www.bloodjournal.org From corresponds to splicing of exon 7 to exon 9, with skipping of exon 8. The upper band corresponds to the wild-type LMAN1 product (exons 7-8-9). Sequencing of intron 7 demonstrated a heterozygous 4 nucleotide (GGTT) insertion 33 bp downstream of exon 7. The 4-nt insertion may be responsible for this aberrant splicing, although an effect of another more distant mutation cannot be excluded. The wild-type product could represent residual normal splicing for the same allele. Alternatively, the second allele may carry an unidentified mutation that markedly reduces transcription or mRNA processing.
Missense mutations disrupt LMAN1-MCFD2 complex formation
We identified a heterozygous missense LMAN1 mutation (C475R) in the proband of an Argentinean family of Italian origin (B17). No other mutations were found in this patient. RT-PCR analysis of lymphoblast RNA revealed that only the missense allele is expressed at the mRNA level, indicating that the second LMAN1 allele in this patient carries an unidentified mutation that results in a cis-defect in transcription or mRNA stability. Cysteine 475 plays an important role in forming disulfide-linked homodimers and homohexamers of LMAN1. Substitution of C475 with alanine has previously been reported to abolish homohexamer formation without affecting homodimer formation 18, 19 .
LMAN1
C475A was shown to exhibit impaired transport out of the ER 18 , but retained a normal intracellular localization pattern 19 . We analyzed cell lysates of lymphoblasts derived from the proband of B17. No endogenous LMAN1 was detectable by Western blot analysis (Fig. 1A) , though upon immunoprecipitation of lysates from 5 X 10 6 cells, a trace amount of LMAN1 was detected (Fig. 1B) . This is in contrast to the reported For personal use only. on July 14, 2017. by guest www.bloodjournal.org From C475A substitution, which exhibited a turnover comparable to the wild-type protein 18 .
In addition to disrupting a disulfide bond that is critical for homohexamer formation, the C475R mutation presumably further compromises LMAN1 folding, leading to ERassociated protein degradation. However, treatment of cells with the potent proteasome inhibitors MG132 and lactacystin only slightly increased the amount of LMAN1 accumulation (Fig. 1C) , suggesting that degradation of LMAN1 C475R is mediated largely through a proteasome-independent pathway.
We previously showed that the I136T mutation in MCFD2 identified in B9 and a Venezuala family (family 9, ref 6 ) abolished binding to LMAN1 in an in vitro transfection assay 6 . To further study the endogenous behavior of this mutant, we performed co-immunoprecipitation analysis in lymphoblasts derived from a Venezuelan patient homozygous for the I136T mutation. Cell lysates were immunoprecipitated with anti-MCFD2 and analyzed by Western blotting with anti-MCFD2 or anti-LMAN1. A small amount of MCFD2 I136T was detected, at a level higher than that observed in LMAN1 mutant lymphoblasts (Fig. 1B) . A trace amount of LMAN1 also coimmunoprecipitated with MCFD2 I136T (Fig. 1B) . Taken together, these data suggest that LMAN1 and MCFD2 I136T retain a weak interaction. However, the residual amount of LMAN1-MCFD2 complex is apparently either functionally deficient or of insufficient quantity to support FV and FVIII secretion.
Discussion
We report the analysis of LMAN1 and MCFD2 mutations in 10 previously patients are from the Mediterranean region [3] [4] [5] [6] [20] [21] [22] , an increasing number of cases have been identified in other geographic regions 4, 5, 15, 16, 23, 24 . A high percentage of F5F8D patients are associated with known consanguinity and/or are homozygous for a single mutation, suggesting that the geographic distribution of this disease is due at least in part to the varying prevalence of consanguineous marriages, rather than specific positive selection for heterozygous carriers.
All previously reported LMAN1 mutations were predicted to be null, leading to the speculation that even a trace amount of functional LMAN1 expression may be sufficient to support normal FV and FVIII trafficking. However, we detected a low level of LMAN1-MCFD2 complex in patient lymphoblasts carrying either the LMAN1 C475R mutation (data not shown) or the MCFD2 I136T mutation (Fig. 1) . The LMAN1-
MCFD2
I136T complex may retain residual FVIII-binding activity, since MCFD2 carrying the similar D129E mutation was shown to bind FVIII 11 . The latter observation suggests that a threshold level of LMAN1-MCFD2 activity above that observed for the LMAN1-MCFD2 I136T complex may be required for the intracellular trafficking of FV and FVIII, though we cannot rule out the possibility that the LMAN1-MCFD2 I136T interaction may be further weakened in more relevant cells such as hepatocytes in vivo. These results also suggest that targeting the LMAN1-MCFD2 complex as a therapeutic approach to anticoagulation is likely to require marked reduction of one or both components of this protein complex.
